Drug Delivery Systems: Entering the Mainstream

  title={Drug Delivery Systems: Entering the Mainstream},
  author={Theresa M. Allen and Pieter R. Cullis},
  pages={1818 - 1822}
Drug delivery systems (DDS) such as lipid- or polymer-based nanoparticles can be designed to improve the pharmacological and therapeutic properties of drugs administered parenterally. Many of the early problems that hindered the clinical applications of particulate DDS have been overcome, with several DDS formulations of anticancer and antifungal drugs now approved for clinical use. Furthermore, there is considerable interest in exploiting the advantages of DDS for in vivo delivery of new drugs… 

Targeting Liposomal Nanomedicine to Cancer Therapy

  • J. ZhongL. Dai
  • Biology, Medicine
    Technology in cancer research & treatment
  • 2012
Recent advances in this field involving conventional anticancer drugs as well as the new genetic drugs with the potentials to offer new treatments in area of cancer therapy are discussed.

Nanoscale delivery systems for multiple drug combinations in cancer.

Some general considerations for optimizing multiply drug delivery, including drug-release profiles and loading strategies are discussed, which are likely to be potential targets in combination therapy as well.

Nanotechnology: A Focus on Nanoparticles as a Drug Delivery System

This review will provide an in-depth discussion on the previous development of nanoparticle-based drug delivery systems (DDS) and discuss original research data that includes the therapeutic

Polymeric nanomaterials in drug delivery

Micro and nano drug delivery systems in cancer therapyArticle

A great number of new drug delivery technologies have been optimised including the micro and nano-systems as well as polymer conjugation, which would not only improve drug administration and the efficiency and safety of conventional chemotherapies, but also revolutionize the pharmaceutical and biomedical industries in cancer therapy.

Functionalization of protein-based nanocages for drug delivery applications.

This review aims to give an overview of different types of modifications of protein-based nanocontainers for drug delivery applications.

Enhancing the pharmacokinetic/pharmacodynamic properties of therapeutic nucleotides using lipid nanoparticle systems.

It is envisioned that the significant improvements in potency and safety, largely driven by the development of LNP encapsulated siRNA drugs, will be translatable to other types of genetic drugs and enable the rapid development of potent molecular tools and drugs.

Advances and challenges of nanotechnology-based drug delivery systems

Using the tools of nanotechnology, drug delivery systems within the nanometer size regime can be developed to alter both pharmacological and therapeutic effects of drug molecules, and offer superior advantages, such as altered pharmacokinetic behaviour and improved payload, over traditional large-scale systems.



Small-scale systems for in vivo drug delivery

Micro- and nanotechnologies are enabling the design of novel methods such as radio-frequency addressing of individual molecules or the suppression of immune response to a release device, but current challenges include the need to balance the small scale of the devices with the quantities of drugs that are clinically necessary.

Chemical approaches to triggerable lipid vesicles for drug and gene delivery.

This work reviews the chemistries that have recently been applied to exploit the pH and redox potential triggers so as to release vesicle contents in the appropriate biological location.

The dawning era of polymer therapeutics

  • R. Duncan
  • Biology, Chemistry
    Nature Reviews Drug Discovery
  • 2003
The successful clinical application of polymer–protein conjugates, and promising clinical results arising from trials with polymer–anticancer-drug conjugate, bode well for the future design and development of the ever more sophisticated bio-nanotechnologies that are needed to realize the full potential of the post-genomic age.

Effect of pegylation on pharmaceuticals

How PEGylation can result in drugs that are often more effective and safer, and which show improved patient convenience and compliance are reviewed.

Myths concerning the use of cationic liposomes in vivo

This review will highlight the features of liposomes that contribute to successful delivery, gene expression and efficacy and will allow broad use ofliposomal complexes to treat or cure human diseases or disorders.

Recent trends in the use of polysaccharides for improved delivery of therapeutic agents: pharmacokinetic and pharmacodynamic perspectives.

  • R. Mehvar
  • Biology, Chemistry
    Current pharmaceutical biotechnology
  • 2003
Four recent examples of polysaccharide-based delivery systems involving specific drugs/imaging agents are reviewed in detail in terms of their development, pharmacokinetics, and pharmacodynamics, suggesting that macromolecular poly Saccharides are promising agents for improving drug delivery.

Long-circulating and target-specific nanoparticles: theory to practice.

The surface mechanisms, which affords red blood cells long-circulatory lives and the ability of specific microorganisms to evade macrophage recognition, are explored and the rational approaches in the design as well as the biological performance of such constructs are assessed.

Nanoparticulate systems for brain delivery of drugs.

  • J. Kreuter
  • Biology, Chemistry
    Advanced drug delivery reviews
  • 2001

Ligand-targeted therapeutics in anticancer therapy

  • T. Allen
  • Biology, Medicine
    Nature Reviews Cancer
  • 2002
Cytotoxic chemotherapy or radiotherapy of cancer is limited by serious, sometimes life-threatening, side effects that arise from toxicities to sensitive normal cells because the therapies are not

Tumor-Targeted Gene Transfer with DNA Polyplexes

Polyplexes based on polyethylenimine, shielded with polyethylene glycol, and linked to the receptor binding ligands transferrin (Tf) or epidermal growth factor (EGF) were found to mediate efficient gene transfer into tumor cell lines in a receptor-dependent and cell-cycle-dependent manner.